Pharmacotherapy of erectile dysfunction

Pharmacotherapy for erectile dysfunction.

Erectile dysfunction (ED) is defined as the consistent inability to obtain or maintain an erection for satisfactory sexual relations. An estimated 20-30 million men suffer from some degree of sexual dysfunction. The past 20 years of research on erectile physiology have increased our understanding of the biochemical factors and intracellular mechanisms responsible for corpus cavernosal smooth mu...

Research in pharmacotherapy for erectile dysfunction

Although oral phosphodiesterase-5 (PDE5) inhibitors are generally accepted as an effective therapy for erectile dysfunction (ED), men with ED from diabetes or radical prostatectomy respond poorly to these drugs. Many researchers have tried to develop novel therapeutics that target alternative molecular pathways. A group of therapeutics belongs to centrally acting agents that target dopamine and...

AB028. Current status of pharmacotherapy for erectile dysfunction

The men’s desire to have larger and longer penis have created endless medical demands throughout human history. Until up to date, various medical skills for penile augmentation have developed in aspect of experimental and clinical outcome. Recently with throwing away socially unacceptable ideas, the need for penile augmentation is considered as equivalent level with mammoplasty for breast augme...

Current Perspectives on Pharmacotherapy Treatments for Erectile Dysfunction

Contemporary intracavernous pharmacotherapy for erectile dysfunction in the aging male

Anthony J Bella1†, William O Brant1 & Gerald B Brock2 †Author for correspondence 1University of California, Department of Urology, San Francisco, CA 94143–0738, USA Tel.: +1 415 789 5109; Fax: +1 415 476 8849; E-mail: abella@ urology.ucsf.edu; [email protected] 2University of Western Ontario, Department of Surgery, Division of Urology, St Joseph’s Health Center, F-122, 268 Grosvenor Street,...